Gupta Prachi, Chen Changliang, Chaluvally-Raghavan Pradeep, Pradeep Sunila
Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Cancers (Basel). 2019 Jun 26;11(7):894. doi: 10.3390/cancers11070894.
Increasing evidence suggests that the immune system plays a dynamic role in the progression of ovarian cancer, the deadliest gynecological malignancy worldwide. Accumulation of tumor-infiltrating lymphocytes has been associated with increased survival in ovarian cancer patients, and diverse interactions among immune cells in the tumor microenvironment determine tumor progression. While the regulatory functions of T cells among tumor-infiltrating lymphocytes are well defined and also involve therapeutic interventions, the role of B cells in ovarian cancer progression is still limited to their impact on survival. Recent studies have identified both pro- and anti-tumor responses of B cells in solid tumors, as different subsets of B cells play diverse roles in progression. Thus, in-depth characterization of B cell subtypes in each disease stage is crucial for understanding the importance and therapeutic potential of these cells in ovarian cancer. In this review, we summarize current knowledge about B cells in ovarian cancer and discuss emerging therapeutic interventions that could harness B cells to combat this deadly disease.
越来越多的证据表明，免疫系统在卵巢癌（全球最致命的妇科恶性肿瘤）的进展中发挥着动态作用。肿瘤浸润淋巴细胞的积累与卵巢癌患者生存率的提高相关，肿瘤微环境中免疫细胞之间的多种相互作用决定了肿瘤的进展。虽然肿瘤浸润淋巴细胞中T细胞的调节功能已得到充分明确，且也涉及治疗干预，但B细胞在卵巢癌进展中的作用仍仅限于其对生存的影响。最近的研究已经确定了实体瘤中B细胞的促肿瘤和抗肿瘤反应，因为不同的B细胞亚群在进展中发挥着不同的作用。因此，深入表征每个疾病阶段的B细胞亚型对于理解这些细胞在卵巢癌中的重要性和治疗潜力至关重要。在这篇综述中，我们总结了目前关于卵巢癌中B细胞的知识，并讨论了利用B细胞对抗这种致命疾病的新兴治疗干预措施。
